{"id":12712,"date":"2026-02-02T18:56:44","date_gmt":"2026-02-02T15:56:44","guid":{"rendered":"https:\/\/nesiller.com\/signatera-minimal-residual-disease-mrd\/"},"modified":"2026-10-28T11:25:58","modified_gmt":"2026-10-28T08:25:58","slug":"signatera-minimal-residual-disease-mrd","status":"publish","type":"page","link":"https:\/\/nesiller.com\/en\/oncology\/signatera-minimal-residual-disease-mrd\/","title":{"rendered":"Signatera – Minimal Residual Disease (MRD)"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Oncology<\/a><\/div>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Signatera\u2122 & Latitude<\/h1>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tThe first FDA-approved MRD technology with Signatera\u2122, and tissue-free monitoring with Latitude\u2122.<\/span>\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tTest brochure<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSample Report<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Nesiller provides Signatera\u2122 solutions as Natera\u2019s sole authorized distributor in T\u00fcrkiye.<\/strong><\/h4>

\u00a0<\/p>

What Is a ctDNA Test?<\/strong><\/p>

Signatera<\/a><\/strong>\u2122 is a highly sensitive, tumor-informed Minimal Residual Disease (MRD) test. By analyzing circulating tumor DNA (ctDNA) in the blood, it helps identify the risk of recurrence at an early stage, monitor treatment response, and support clinical decision-making. The Signatera\u2122 test is performed at Natera laboratories in the United States<\/strong>. It is an FDA-approved<\/strong> MRD test and is recommended by international guidelines<\/strong> for several tumor types, including colorectal cancer, breast cancer, and non-small cell lung cancer<\/strong>.<\/p>

A positive Signatera\u2122 result<\/strong> indicates that traces of tumor-derived DNA have been detected in the blood. In other words, it indicates an increased risk of disease recurrence, as demonstrated in studies such as IMvigor<\/a> and GALAXY. A negative Signatera\u2122 result<\/strong> means that no traces of tumor-derived DNA were detected in the blood at the time of testing. However, a negative result does not mean that the disease will not recur in the future.<\/strong> Therefore, depending on the physician\u2019s assessment, repeat Signatera\u2122 testing at regular intervals, typically every 3\u20136 months<\/strong>, may be recommended.<\/p>

In MRD testing, the tumor-informed approach uses the genetic alterations specific to a patient\u2019s own tumor to provide personalized results. Other MRD tests, known as tumor-naive tests and performed using blood samples without first establishing a personalized tumor profile, may offer more limited sensitivity compared with the tumor-informed approach.<\/em><\/p>

What Questions Can Signatera\u2122 Help Address?<\/strong><\/p>